Alembic Pharma posts 17 pecent increase in Q4 profit
Bengaluru: Alembic Pharma, an Indian generic drug manufacturer, has announced a 17 percent rise in fourth-quarter profit, propelled by strong sales, especially in the crucial North American market.Consolidated profit rose to 1.78 billion rupees ($21.3 million) in the three months ended March 31, from 1.53 billion rupees a year earlier.As per Reuters Report, Indian generic drugmakers like...
Bengaluru: Alembic Pharma, an Indian generic drug manufacturer, has announced a 17 percent rise in fourth-quarter profit, propelled by strong sales, especially in the crucial North American market.
Consolidated profit rose to 1.78 billion rupees ($21.3 million) in the three months ended March 31, from 1.53 billion rupees a year earlier.
Headquartered in India, Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. It is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.
Read also: Alembic Pharma gets tentative USFDA nod for breast cancer drug Ribociclib in March Quarter
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd